Clinical Trial

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-04-03; most recent amendment 2026-05-14.
Status change: Recruiting → Active, Not Recruiting 2023-01-15
Status change: Active, Not Recruiting → Recruiting 2022-03-01
Status change: Recruiting → Active, Not Recruiting 2021-01-31
Status change: Not Yet Recruiting → Recruiting 2017-10-27
Trial Details
NCT Number NCT03104842
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions Multiple Myeloma
Enrollment 246 participants
Start Date 2017-08-15
Primary Completion 2026-05 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-15